- Home
- PMM vs CLLS Comparison
PMM vs CLLS Comparison
Compare PMM & CLLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMM
- CLLS
- Stock Information
- Founded
- PMM 1989
- CLLS 1999
- Country
- PMM United States
- CLLS France
- Employees
- PMM N/A
- CLLS N/A
- Industry
- PMM Investment Managers
- CLLS Biotechnology: Pharmaceutical Preparations
- Sector
- PMM Finance
- CLLS Health Care
- Exchange
- PMM Nasdaq
- CLLS Nasdaq
- Market Cap
- PMM 252.3M
- CLLS 299.0M
- IPO Year
- PMM N/A
- CLLS 2007
- Fundamental
- Price
- PMM $5.85
- CLLS $2.85
- Analyst Decision
- PMM
- CLLS Buy
- Analyst Count
- PMM 0
- CLLS 1
- Target Price
- PMM N/A
- CLLS $4.00
- AVG Volume (30 Days)
- PMM 118.3K
- CLLS 199.3K
- Earning Date
- PMM 01-01-0001
- CLLS 08-04-2025
- Dividend Yield
- PMM 4.68%
- CLLS N/A
- EPS Growth
- PMM N/A
- CLLS N/A
- EPS
- PMM 0.23
- CLLS N/A
- Revenue
- PMM N/A
- CLLS $63,438,000.00
- Revenue This Year
- PMM N/A
- CLLS N/A
- Revenue Next Year
- PMM N/A
- CLLS $4.90
- P/E Ratio
- PMM $26.52
- CLLS N/A
- Revenue Growth
- PMM N/A
- CLLS 223.09
- 52 Week Low
- PMM $5.00
- CLLS $1.10
- 52 Week High
- PMM $6.42
- CLLS $3.24
- Technical
- Relative Strength Index (RSI)
- PMM 48.84
- CLLS 59.27
- Support Level
- PMM $5.77
- CLLS $2.71
- Resistance Level
- PMM $5.93
- CLLS $3.08
- Average True Range (ATR)
- PMM 0.05
- CLLS 0.20
- MACD
- PMM -0.00
- CLLS -0.03
- Stochastic Oscillator
- PMM 47.06
- CLLS 61.67
About PMM Putnam Managed Municipal Income Trust
Putnam Managed Municipal Income Trust is a closed-end management investment company. Its investment objective is to seek a high level of current income exempt from federal income tax by investing in a diversified portfolio of tax-exempt municipal securities. The Fund invests in various sectors such as healthcare, retirement community, private higher education, housing-backed, essential service utilities, and state-backed bonds.
About CLLS Cellectis S.A.
Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.